Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

Brian Laden - aVenture Research

Brian Laden

AddedMar 31, 2024

UpdatedOct 16, 2026

Brian Laden

Brian Laden

Founder & CEO, Appello Pharmaceuticals

Brian Laden's Career

TriStar Health Partners

Investment Firm

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

Nashville, TN, US

Co-Founder

GenomOncology

Seed$2.9MCleveland, OH, US

Board Member· Board

Cerebrotech Medical Systems

Series A$7.7MPleasanton, CA, US

Board Member· Board

Molecular Sensing

Series A$7.9MNashville, TN, US

Board Member· Board

Appello Pharmaceuticals

Series B$29MNashville, TN, US

Founder & CEO· C-Suite · Management

Founder

NuSirt Sciences

Public$16MNashville, TN, US

Board Member· Board

BioStable Science & Engineering

Series C$10.8MAustin, TX, US

Board Member· Board

People Similar to Brian Laden

Ming-Kuei JangBoard Member · Aprinoia Therapeutics

Kuk Hyun KyungBoard Member · Aprinoia Therapeutics

Art PappasCEO · Pappas Capital

Paul TempestBoard Member · Aprinoia Therapeutics

Leadership at TriStar Health Partners

Christopher RandCo-Founder

Similar to TriStar Health Partners

Triathlon Medical Venture PartnersCincinnati, OH, USest. 2003Triathlon Medical Venture PartnersCincinnati, OH, US · est. 2003

Triathlon Medical Venture Partners: A US-based venture capital firm specializing in life science, biomedical, and healthcare sectors.

Investment Firm30

Alliance Healthcare PartnersScottsdale, AZ, USest. 2012Alliance Healthcare PartnersScottsdale, AZ, US · est. 2012

Alliance Healthcare Partners: A US-based venture capital firm investing in healthcare and technology sectors.

Investment Firm15

ValtruisNew York City, NY, USest. 2021ValtruisNew York City, NY, US · est. 2021

Valtruis: A healthcare investment platform transforming the industry by funding and partnering with innovative leaders.

Investment Firm11

Tri-State Investment GroupChapel Hill, NC, USTri-State Investment GroupChapel Hill, NC, US

Tri-State Investment Group: A Chapel Hill-based venture capital firm specializing in early to mid-stage investments.

Investment Firm5

Leadership at GenomOncology

Jeff ShinerBoard Member

John DoulisBoard Member

Manuel GlyniasBoard Member

Lee ZapisBoard Member

Brad WertzBoard Member

Similar to GenomOncology

Onc.AISan Carlos, CA, USOncology Softwareest. 2020Onc.AISan Carlos, CA, US · est. 2020

Creating precision oncology software for clinical use, with a focus on physician-centered products.

Series A · $31M30

Leadership at Cerebrotech Medical Systems

Joe Cook JrBoard Member

Mitch LevinsonCo-Founder

Boris RubinskyCo-Founder

Carl O'ConnellCEO

Martin DieckBoard Member

Issie RabinovitchBoard Member

Similar to Cerebrotech Medical Systems

Sense DiagnosticsCincinnati, OH, USMedical Devicesest. 2014Sense DiagnosticsCincinnati, OH, US · est. 2014

Sense Neuro Diagnostics develops non-invasive tech for rapid stroke detection and brain injury monitoring.

Series B · $14.2M15

Leadership at Molecular Sensing

William E RichCEO

Similar to Molecular Sensing

Montana MolecularBozeman, MT, USBiosensors, Drug Discoveryest. 2007Montana MolecularBozeman, MT, US · est. 2007

Montana Molecular, based in Bozeman, US, specializes in developing fluorescent biosensors and drug discovery tools.

Pre-Seed · $2M11

MouSensorNew York City, NY, USSoftwareest. 2016MouSensorNew York City, NY, US · est. 2016

MouSensor, Inc.: A biotech firm providing innovative software to digitize the sense of smell.

InfusenseMemphis, TN, USBiosensors, Drug Quantificationest. 2009InfusenseMemphis, TN, US · est. 2009

Infusense LLC: A leading provider of comprehensive R&D services in engineering and life sciences.

Siscapa Assay TechnologiesWashington, D.C., DC, USAssays, Bioresearchest. 2011Siscapa Assay TechnologiesWashington, D.C., DC, US · est. 2011

Siscapa Assay Technologies: Leading provider of MRM mass spectrometry and bio-research solutions since 2011.

Pre-Seed · $1.6M30

Leadership at Appello Pharmaceuticals

Howie FurstBoard Member

P. Jeffrey ConnBoard Member

Vaughn BrysonBoard Member

Bill SlatteryBoard Member

Joe CookBoard Member

Similar to Appello Pharmaceuticals

Apellis PharmaceuticalsWaltham, MA, USPharmaceuticals, Therapeuticsest. 2008Apellis PharmaceuticalsWaltham, MA, US · est. 2008

US-based Apellis Pharmaceuticals develops therapeutic compounds for autoimmune and inflammatory diseases globally.

Public · $168.5M500

Leadership at NuSirt Sciences

Byron SmithBoard Member

Michael ZemelFounder

Similar to NuSirt Sciences

OrsoBioPalo Alto, CA, USBiopharmaceuticalsest. 2021OrsoBioPalo Alto, CA, US · est. 2021

OrsoBio: A clinical-stage biopharmaceutical firm innovating therapies for severe metabolic disorders.

Series A · $62.3M11

Nimbus TherapeuticsCambridge, MA, USDrugs, Therapeuticsest. 2009Nimbus TherapeuticsCambridge, MA, US · est. 2009

Nimbus Discovery: A US-based clinical-stage biotech firm specializing in metabolic, oncology, and immune-inflammatory treatments.

Public · $637M112

Lipidio PharmaceuticalsSan Diego, CA, USPharmaceuticalsest. 2018Lipidio PharmaceuticalsSan Diego, CA, US · est. 2018

Lipidio Pharma: Advancing molecules for dermatological and metabolic diseases treatment.

Series A · $20M5

Navitor PharmaceuticalsCambridge, MA, USPharmaceuticalsest. 2010Navitor PharmaceuticalsCambridge, MA, US · est. 2010

Navitor Pharmaceuticals: A biopharmaceutical company innovating novel medicines via cellular nutrient signaling.

Series C · $98.2M36

Leadership at BioStable Science & Engineering

John WheelerBoard Member

David StrongBoard Member

Dave AdairBoard Member

Similar to BioStable Science & Engineering

Thubrikar Aortic ValveNorristown, PA, USMedical Devicesest. 2010Thubrikar Aortic ValveNorristown, PA, US · est. 2010

South Dakota-based Thubrikar Aortic Valve, a key player in the healthcare sector.

Angel · $2.9M5

Arbor Surgical TechnologiesIrvine, CA, USMedical Devicesest. 2002Arbor Surgical TechnologiesIrvine, CA, US · est. 2002

Arbor Surgical Technologies: Innovating in heart valve replacement with advanced medical devices and tools.

Series C · $50.8M30

EmbolineSanta Cruz, CA, USMedical Devicesest. 2011EmbolineSanta Cruz, CA, US · est. 2011

Emboline: Innovating heart valve repair with total embolic protection medical devices.

Series D · $75M6

ArstasisRedwood City, CA, USMedical Devicesest. 2004ArstasisRedwood City, CA, US · est. 2004

Arstasis: Innovating cardiac device manufacturing for enhanced clinical procedures since 2006.

Series E · $95.4M75

xCuresOakland, CA, USOncology Softwareest. 2018

xCuresOakland, CA, US · est. 2018

AI-based precision oncology platform revolutionizing treatment through genomics and precision medicine.

Series B · $84M45

MyCancerDBStockbridge, VT, USGenomic Analysisest. 2019MyCancerDBStockbridge, VT, US · est. 2019

MyCancerDB: A platform leveraging genomic data for personalized cancer treatment options.

D2G OncologyMountain View, CA, USCancer Therapeuticsest. 2018D2G OncologyMountain View, CA, US · est. 2018

D2G Oncology: Transforming precision cancer therapeutics through advanced genomics.

Series A · $8.7M15

Branchpoint TechnologiesIrvine, CA, USMedical Devicesest. 2013

Branchpoint TechnologiesIrvine, CA, US · est. 2013

Branchpoint Technologies: Advancing neuromonitoring and neurocritical care through innovative medical device R&D.

Series D · $4M4

TraumatecSan Antonio, TX, USMedical Devicesest. 2007TraumatecSan Antonio, TX, US · est. 2007

TraumaTec: Innovating non-invasive, disposable medical devices for targeted brain cooling and injury mitigation.

Precision NeuroscopicsPittsburgh, PA, USMedical Devicesest. 2015Precision NeuroscopicsPittsburgh, PA, US · est. 2015

Pittsburgh-based Precision Neuroscopics develops high-density, non-invasive brain signal detection systems.

Angel · $1.4M8

Woolsey PharmaceuticalsNew York City, NY, USPharmaceuticalsest. 2019

Woolsey PharmaceuticalsNew York City, NY, US · est. 2019

Woolsey Pharmaceuticals: Innovating treatments for challenging diseases, accelerating global health solutions.

Series B · $28.3M9

Aprinoia TherapeuticsCambridge, MA, USDiagnostic Tools, Therapiesest. 2015Aprinoia TherapeuticsCambridge, MA, US · est. 2015

APRINOIA: A global biotech leader in precision neuroscience, innovating diagnostic tools and therapies for neurodegenerative diseases.

Series A · $61.9M75

Avalyn PharmaSeattle, WA, USPharmaceuticalsest. 2011Avalyn PharmaSeattle, WA, US · est. 2011

Avalyn Pharma Inc.: Developing innovative therapies for Idiopathic Pulmonary Fibrosis.

Public · $272.5M27